GHRP-2, also documented under the research name pralmorelin, is a synthetic six-amino-acid growth hormone secretagogue whose disposition is defined by fast absorption, a short circulating life, and a downstream hormone signal that outlasts the peptide itself. The published pharmacology describes peak plasma levels within roughly 15 to 30 minutes and a plasma elimination half-life near 30 minutes, while the growth hormone pulse it provokes persists for one to three hours through downstream growth hormone and IGF-1 rather than sustained peptide levels. These figures come from clinical pharmacology studies rather than an approved United States product label, so they read as characteristic ranges, and GHRP-2 is not an FDA-approved therapeutic in the United States.
GHRP-2 reaches peak plasma concentration within about 15 to 30 minutes and carries a plasma elimination half-life near 30 minutes, while the growth hormone pulse it triggers persists roughly one to three hours through downstream growth hormone and IGF-1.
The circulating half-life of GHRP-2 is short, reported near 30 minutes, so intact peptide roughly halves every half hour and is largely gone within a few hours of the peak. That brevity is typical of a low-molecular-weight peptide with no protective modification, and it is why the published record treats the peptide half-life and the duration of its hormone effect as two separate clocks.
The plasma half-life of GHRP-2 is reported at approximately 30 minutes, a value drawn from clinical pharmacology studies rather than an approved product label.
Growth hormone release after GHRP-2 is fast because the compound draws on a preformed, readily releasable pool in the pituitary somatotrophs rather than requiring new synthesis. Serum growth hormone begins climbing within minutes of an intravenous dose and within about 10 to 15 minutes of a subcutaneous one, with the peak commonly landing 15 to 30 minutes after administration. The route reshapes both the speed and the height of that peak, which is why the published literature reports the two routes separately.
| Parameter | Intravenous | Subcutaneous |
|---|---|---|
| Onset of GH rise | Within a few minutes | ~10-15 minutes |
| Time to peak | ~15-30 min, most abrupt | Slightly later |
| Peak magnitude | Often highest | Modestly blunted |
| Absorption delay | None, direct to circulation | Depot spreads delivery |
Serum growth hormone begins rising within minutes of an intravenous GHRP-2 dose and within about 10 to 15 minutes of a subcutaneous dose, with the peak typically arriving 15 to 30 minutes after administration.
Unlike most small-molecule drugs, GHRP-2 does not lean on the hepatic cytochrome P450 oxidation pathways at all. It is cleared the way the body handles short peptides, broken at its peptide bonds by peptidases in blood, the vascular endothelium, kidney, and liver into inactive fragments and free amino acids. The kidney carries much of that load, both filtering the intact peptide and degrading peptide material within the tubular cells.
GHRP-2 is eliminated by enzymatic proteolysis rather than hepatic cytochrome P450 metabolism, with the kidney filtering and degrading both the intact hexapeptide and its fragments.
Route of administration is one of the largest single influences on how much GHRP-2 reaches the pituitary and how the response is shaped. The published record ranks the routes on a clear bioavailability gradient, with the injectable routes preserving the compound and the non-injectable routes sacrificing progressively more of the dose.
Intravenous administration serves as the 100 percent bioavailability reference for GHRP-2, subcutaneous injection gives good but incomplete absorption, intranasal delivery reaches only low single-digit percentages, and oral dosing yields negligible systemic exposure.
Even though intact GHRP-2 largely disappears from plasma within a few hours, the hormone signal it sets off has a longer footprint that unfolds in stages. The mismatch exists because the peptide triggers release of the body's own stored growth hormone rather than acting as growth hormone, so the released hormone keeps circulating on its own timeline after the trigger is gone.
A single GHRP-2 dose clears from plasma within a few hours, yet the growth hormone it releases stays elevated for roughly one to three hours and the downstream IGF-1 response extends over hours to days.
Both the clearance of GHRP-2 and, even more, the size of the growth hormone response it produces vary considerably between individuals, because physiology gates each side. The published pharmacology attributes most of that spread to age, body composition, renal function, the prevailing hormonal environment, and recent secretagogue exposure.
Age, body composition, renal function, somatostatin and IGF-1 feedback, and recent secretagogue exposure each shift GHRP-2 pharmacokinetics and the growth hormone response, so any single quoted figure describes a typical case rather than a fixed outcome.
GHRP-2 shows a dose-related but saturating response, and the published pharmacology separates peptide exposure from pituitary output to explain it. More peptide raises the growth hormone pulse only up to the point where the somatotrophs hit the limit of their releasable pool, after which added dose piles on circulating peptide and metabolic load without a larger hormone release.
The GHRP-2 growth hormone response rises with dose only up to a saturating ceiling set by the pituitary's releasable pool, beyond which added dose increases circulating peptide and the chance of dose-related effects such as transient cortisol and prolactin rises without enlarging the pulse.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
